French specialty pharmaceutical company, Juvisé Pharmaceuticals, has completed a €400m (US$405.5m) refinancing following the acquisition of the worldwide rights to Pylera, an antimicrobial tri-therapy indicated for gastro-intestinal Helicobacter pylori infections…



